The cell and gene therapy CDMO has completed its new 45,000 sqft facility that included 8 prefabricated cleanroom PODs from G-CON
Matica Biotechnology, a contract development and manufacturing organisation (CDMO) specialising in the clinical and commercial production of cell and gene therapies, has announced the opening of its new 45,000 sqft facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.
Building on years of cell and gene therapy expertise, Matica Bio's new facility is now expanding its capacity as a CDMO - ready to support the biopharmaceutical industry's need for faster delivery of cells and viral vectors that are key components of some of the most promising novel therapies.
The 7,900 sqft POD system from G-CON was planned to serve as the seed preparation suite, upstream and downstream processing suites, fill-finish suite and other auxiliary GMP areas
"The key is faster delivery without sacrificing quality or safety," said Matica Bio CEO Yun Jeong Song. "Our new facility is designed for rapid development, scale-up and production for clinical supply, but our experienced teams provide quality oversight and regulatory guidance necessary to ensure success. Solely committed to our clients' commercialisation goals, we have the expertise and an advanced, modular system that provides the flexibility to adjust resources required depending on client need and product requirements."
G-CON Manufacturing contributed to the build with the engineering design, build and delivery of 8 prefabricated cleanroom PODs.
The 7,900 sqft POD system from G-CON was planned to serve as Matica Bio's seed preparation suite, upstream and downstream processing suites, fill-finish suite and other auxiliary GMP areas. Each POD will also feature dedicated air handling units, a fire protection system, an integrated automation system, and process utility distribution.
G-CON also commissioned the units after delivery as part of the overall project validation effort.
We're aiming to improve multiple components across the cell and gene therapy production process
To keep pace with accelerated clinical development time frames, production complexities and demand, Matica Bio already has two collaborations at the new facility.
First, the company is working with Sartorius to develop and optimise advanced viral vector manufacturing technologies for large-scale vector production.
Matica has also partnered with Texas A&M University's Center for Innovation in Advanced Development and Manufacturing for projects to speed up biotech R&D and commercial manufacturing.
"We're aiming to improve multiple components across the cell and gene therapy production process from ease of manufacturability, to real-time data read-outs, reducing costs, and solving anticipated challenges of large-scale cell culture and viral vector production," said Matica Bio Chief Technology Officer Mike Stewart. "These collaborations are just the start of Matica Bio's commitment to continue building research and expertise for successful product development at this facility and through future expansion."